The Cancer Strategy of Spain’s National Health System provides a framework for immediate action to protect people with cancer from COVID-19 risks and longer-term consequences, while strengthening public-health policy and oncology care across the health system.Its central aim is to mitigate the effects of pandemic-related disruption by rapidly restoring diagnostic and therapeutic activity, maintaining access to safe, continuous and person-centred cancer care, and reducing delays from clinical suspicion to initial treatment.
Maintain cancer diagnosis, treatment, follow-up and clinical-trial activity as safely as possible during periods of COVID-19 transmission, including surgery, systemic treatment and radiotherapy.
Restore population screening for the full target population at recommended intervals, prioritise follow-up after suspicious findings according to malignancy risk, and communicate the safety arrangements for screening attendance.
Reduce diagnostic and treatment delays, recognising that interruptions to screening, reduced diagnoses, restricted access to primary and hospital care, and delayed diagnostic tests may adversely affect survival and quality of life.
Protect clinically vulnerable people with cancer from infection while preserving access to healthcare, including reasonable and safe face-to-face care where needed.
Strengthen cancer prevention and health promotion, including healthy lifestyles and consideration of pandemic-related effects on human papillomavirus and hepatitis B vaccination coverage.
Preserve quality of life by maintaining pain management, psychological support and palliative care in facilities and at home, alongside protected family presence and support at the end of life.
Stratify adverse-outcome risk by tumour type, patient characteristics and clinical situation to guide agreed priorities for diagnosis and treatment when resources are scarce.
The approach combines locally adaptable service recovery with coordinated national action through the Ministry of Health, autonomous communities, scientific societies, patient associations and the Cancer Strategy’s monitoring and evaluation structures.It relies on protected care pathways, clinically justified treatment adaptation, digital and home-based service models, multidisciplinary decision-making, and evidence-informed prioritisation to sustain cancer care while minimising infection risk.
Implement agreed priorities through the Ministry of Health and autonomous communities, adapting delivery to each autonomous community while engaging scientific societies and patient associations.
Establish protected diagnostic circuits and maintain a baseline capacity for cancer diagnosis and treatment during peaks of COVID-19 transmission.
Use teleconsultation, telemonitoring, telemedicine and telepharmacy for suitable follow-up and support, while retaining appropriate in-person assessment and accompaniment.
Provide primary-care testing and home-based treatment where appropriate, and combine facility-based and home-based pain, psychological and palliative support.
Adapt treatment safely using approaches that can reduce healthcare visits, including oral chemotherapy, neoadjuvant therapy and hypofractionated radiotherapy, guided by national and international scientific recommendations and consensus.
Maintain multidisciplinary assessment and equip teams to apply shared prioritisation criteria rather than relying solely on case-by-case decisions during resource shortages.
Support patients and families through adapted recommendations, support programmes, telephone information services, remote consultation channels and websites, including information on protection from COVID-19 during face-to-face care.
Assess the pandemic’s impact through available healthcare and epidemiological data from across the National Health System, with the Ministry of Health preparing a collaborative report involving autonomous communities, scientific societies and patient associations.
Evaluate implementation within six months of approval by the plenary of the Interterritorial Council of the National Health System.
Coordinate oversight through the Cancer Strategy monitoring and evaluation committee, which includes scientific and technical coordination, representation from autonomous communities and INGESA, Ministry of Health participation, and involvement from professional, patient, registry, research and specialist organisations.
Recognise that the supplied material does not specify a detailed indicator set, reporting timetable, formal accountability process, budget, funding source or resource allocation for these measures.
Monitoring and evaluation focus on assessing the COVID-19 pandemic’s disruption to cancer prevention, screening, diagnosis, treatment, follow-up and outcomes, while using the Cancer Strategy of Spain’s National Health System as the governance framework for recovery and longer-term action.A monitoring and evaluation committee supports this framework, with scientific and technical coordination, representation from autonomous communities, the Ministry of Health and INGESA, and participation by relevant technical and specialist bodies.
The evidence base includes published modelling on the potential consequences of delayed diagnosis and treatment. A three-month delay in surgery was associated with a relevant survival effect, particularly for aggressive tumours, while a population-register modelling exercise estimated a 5.8% to 16% increase in five-year deaths for breast, colorectal and lung cancers under specified diagnostic-delay scenarios.These findings support the priority given to restoring diagnostic and therapeutic activity, maintaining screening, and reducing time from clinical suspicion to first treatment.
Accountability is primarily organised through collaborative governance rather than a fully specified performance-management system. The proposal was developed following a motion approved by the Senate Health and Consumer Affairs Committee and agreement through the Cancer Strategy’s Monitoring and Evaluation Committee.Delivery and review involve the Ministry of Health, autonomous communities, scientific societies and patient associations.The committee includes institutional representation from autonomous communities and INGESA, while its technical participation includes professional societies, cancer and patient organisations, registries, research bodies and specialist organisations.
The supplied material does not specify a comprehensive indicator set, indicator definitions, baselines, targets, data-collection frequency, reporting timetable, surveillance platform, public reporting process or sanctions for non-performance.It identifies data analysis, a Ministry of Health report, committee oversight and a six-month implementation evaluation, but does not provide further detail on evaluation methods or formal accountability procedures.
No explicit costing or financing framework is provided for the proposed COVID-19 cancer-care measures. The available material does not set out budgets, expenditure ceilings, financial allocations, funding sources, funding gaps, resource-mobilisation targets, cost-effectiveness assessments or economic assumptions.
The absence of quantified financial information means that the resource implications of restoring delayed diagnostics and treatment, maintaining screening coverage, protecting vulnerable patients, expanding remote care and sustaining home and palliative services cannot be assessed from the supplied text.No funding responsibilities are allocated among the Ministry of Health, autonomous communities, health services, scientific societies or patient associations.